Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tigilidine vs sufentanil for postoperative PCIA after major laparoscopic abdominal surgery
ChiCTR2600125177Phase 4Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, triple-blind trial of tegileridine in postoperative pain (2 arms), sponsored by Shanghai General Hospital. Primary endpoint: Cumulative pain intensity at rest within the first 24 hours postoperatively. Planned start May 2026; status: not yet recruiting.
02
Drugs
tegileridine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ChiCTR2600125177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125177.